Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Crizotinib (Xalkori™)

Last Updated: 01/12/18


Crizotinib - Chemical Structure

Index

  1. Basic Information
  2. Side Effects
  3. Added Facts
  4. Sources

1. Basic Information

Trade Name Xalkori™
Chemical Compound   Crizotinib
Other Names PF-2341066, PF-02341066, PF2341066, PF-2341066, PF 2341066
Pharmaceutical Companies Pfizer
NF2 Trial Availability USA
Taken By Pfizer
Tumor Target Schwannoma
NF2 Trials Recruiting Trial: NCT02465060
Inhibitor of FAK1 (PTK2) - PI3K/Akt/mTOR signaling pathway
IUPAC/Chemical Name (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
Molecular Formula C21H22Cl2FN5O

2. Side Effects

  • fatigue
  • nausea
  • mucositis
  • rash
  • constipation
  • vomiting
  • dyspnea
  • cough

3. Added Facts

  • Also In Use For: Breast Cancer, solid tumor cancer
  • Solubility: Soluble in DMSO, not in water. Dimethyl Sulfoxide (DMSO) is an organosulfur compound with the formula (CH3)2SO.
  • Mammalian target of rapamycin (mTOR) serine/threonine kinase (dual mTOR Complex 1 and 2 inhibitor, mTORC1 and mTORC2)
  • Inhibitor: inhibits the membrane receptor MET and activation of the MET signaling pathway

4. Sources and More Information

  1. Troutman, Scott, et al. "Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1." Oncotarget 7.34 (2016): 54515. doi: 10.18632/oncotarget.10248
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342359/
  2. National Center for Biotechnology Information. PubChem Compound Database; "CID=11626560", (accessed Jan. 12, 2018) https://pubchem.ncbi.nlm.nih.gov/compound/11626560
  3. MedKoo Biosciences. "Crizotinib - MedKoo CAT#: 202222" (accessed Jan. 12, 2018) http://www.medkoo.com/products/4537